Financial objectives

Sales growth, core operating margin: discover our financial objectives for 2017 and our 2020 outlook.

 

2017 financial objectives*

The Group has set the following financial targets for 2017 assuming a successful closing of the Onivyde® transaction with Merrimack by the end of the first quarter 2017, and of the Consumer Healthcare transaction with Sanofi in the second quarter of 2017:

  • Specialty Care sales growth year-on-year greater than +18.0%
  • Primary Care sales growth year-on-year greater than +4.0%
  • Core operating margin (excluding amortization of intangible assets) greater than 24% of net sales 

 

 

FY17 guidance

 

Specialty Care sales growth Growth >18% 
Primary Care sales growth Growth >4%
Core Operating margin >24%

 

2020 outlook

On 2 July 2015, the Group provided financial guidance for 2020 in terms of sales and operating margin.

On 1 March 2016, these forecasts were updated to reflect the contribution of cabozantinib, in-licensed worldwide outside the United States, and Japan:

  • Sales in excess of 2.0 billion euros;
  • Core operating margin greater than 26% (including amortization of intangible assets).

These forecasts will be updated in the second quarter of 2017 to include notably the recent acquisitions of Onivyde® and the new Consumer Health Care products announced in the beginning of 2017, as well as the updated definition of Core financial measures.

 

*Sales objectives are set at constant currency

Last update 23/02/2017